Synthetic biology company Zymergen to cut 120 jobs after 1st product falters

Zymergen, which went public in April in a half-billion IPO, said it is conducting a "full assessment" of its target markets.

Source: bizjournals.com Health Care:Biotechnology headlines - September 23, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news